Horizon Therapeutics Public Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Horizon Therapeutics Public stock.
View analyst ratings for Horizon Therapeutics Public or view top-rated stocks.

Wall Street analysts have given Horizon Therapeutics Public a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Horizon Therapeutics Public wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Horizon Therapeutics Public saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 4,090,000 shares, an increase of 21.0% from the August 15th total of 3,380,000 shares. Based on an average trading volume of 1,320,000 shares, the short-interest ratio is currently 3.1 days. Currently, 1.9% of the shares of the company are short sold.
View Horizon Therapeutics Public's Short Interest.

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Horizon Therapeutics Public.

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Tuesday, August, 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.87 by $0.75. The biopharmaceutical company earned $832.55 million during the quarter, compared to analyst estimates of $697.69 million. Horizon Therapeutics Public had a net margin of 20.27% and a trailing twelve-month return on equity of 27.41%. The firm's quarterly revenue was up 79.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.40 earnings per share.
View Horizon Therapeutics Public's earnings history.

Horizon Therapeutics Public's stock was trading at $30.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HZNP stock has increased by 253.8% and is now trading at $107.95.
View which stocks have been most impacted by COVID-19.

Horizon Therapeutics Public updated its FY 2021 earnings guidance on Wednesday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.03 billion-$3.13 billion, compared to the consensus revenue estimate of $2.81 billion.

10 brokerages have issued 1 year target prices for Horizon Therapeutics Public's shares. Their forecasts range from $100.00 to $135.00. On average, they anticipate Horizon Therapeutics Public's share price to reach $118.56 in the next year. This suggests a possible upside of 9.8% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public or view top-rated stocks among Wall Street analysts.

70 employees have rated Horizon Therapeutics Public CEO Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among Horizon Therapeutics Public's employees.

Some companies that are related to Horizon Therapeutics Public include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Omeros (OMER).
View all of HZNP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Horizon Therapeutics Public's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.82%), FMR LLC (6.56%), BlackRock Inc. (6.19%), JPMorgan Chase & Co. (2.66%), State Street Corp (2.41%) and William Blair Investment Management LLC (1.95%). Company insiders that own Horizon Therapeutics Public stock include Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends for Horizon Therapeutics Public.

HZNP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, BNP Paribas Arbitrage SA, Eagle Asset Management Inc., Vanguard Group Inc., American Century Companies Inc., Westfield Capital Management Co. LP, and Marshall Wace North America L.P.. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Andy Pasternak, Barry Moze, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, Vikram Karnani, and William F Daniel.
View insider buying and selling activity for Horizon Therapeutics Public or view top insider-selling stocks.

HZNP stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Macquarie Group Ltd., State Street Corp, Point72 Asset Management L.P., FMR LLC, Bank of Montreal Can, Woodline Partners LP, and Millennium Management LLC.
View insider buying and selling activity for Horizon Therapeutics Public or or view top insider-buying stocks.

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HZNP stock can currently be purchased for approximately $107.95.

Horizon Therapeutics Public has a market capitalization of $24.39 billion and generates $2.20 billion in revenue each year. The biopharmaceutical company earns $389.80 million in net income (profit) each year or $3.88 on an earnings per share basis.

Horizon Therapeutics Public employs 1,395 workers across the globe.

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..

Horizon Therapeutics Public was founded in 2008.

The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

Horizon Therapeutics Public is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6.

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at (531) 772-2100 or via email at [email protected]